X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs FULFORD INDIA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES FULFORD INDIA PIRAMAL ENTERPRISES/
FULFORD INDIA
 
P/E (TTM) x 10.8 398.8 2.7% View Chart
P/BV x 1.9 6.2 29.8% View Chart
Dividend Yield % 0.9 0.1 1,038.4%  

Financials

 PIRAMAL ENTERPRISES   FULFORD INDIA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-18
FULFORD INDIA
Mar-14
PIRAMAL ENTERPRISES/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs3,083942 327.3%   
Low Rs1,902450 422.7%   
Sales per share (Unadj.) Rs589.7691.4 85.3%  
Earnings per share (Unadj.) Rs284.011.5 2,478.1%  
Cash flow per share (Unadj.) Rs310.515.4 2,021.7%  
Dividends per share (Unadj.) Rs25.002.00 1,250.0%  
Dividend yield (eoy) %1.00.3 349.0%  
Book value per share (Unadj.) Rs1,467.0380.0 386.0%  
Shares outstanding (eoy) m180.273.90 4,622.3%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x4.21.0 419.9%   
Avg P/E ratio x8.860.7 14.5%  
P/CF ratio (eoy) x8.045.3 17.7%  
Price / Book Value ratio x1.71.8 92.8%  
Dividend payout %8.817.4 50.4%   
Avg Mkt Cap Rs m449,3322,714 16,553.6%   
No. of employees `0006.80.4 1,541.2%   
Total wages/salary Rs m19,881505 3,936.9%   
Avg. sales/employee Rs Th15,535.66,073.0 255.8%   
Avg. wages/employee Rs Th2,905.41,137.4 255.4%   
Avg. net profit/employee Rs Th7,482.5100.7 7,432.3%   
INCOME DATA
Net Sales Rs m106,3102,696 3,942.7%  
Other income Rs m2,595125 2,069.6%   
Total revenues Rs m108,9062,822 3,859.4%   
Gross profit Rs m51,599-46 -111,204.1%  
Depreciation Rs m4,77315 31,403.3%   
Interest Rs m29,78310 313,505.3%   
Profit before tax Rs m19,63854 36,165.2%   
Minority Interest Rs m2,8010-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-28,76410 -299,627.1%   
Profit after tax Rs m51,20345 114,547.7%  
Gross profit margin %48.5-1.7 -2,820.5%  
Effective tax rate %-146.517.7 -828.5%   
Net profit margin %48.21.7 2,905.3%  
BALANCE SHEET DATA
Current assets Rs m118,1541,738 6,797.1%   
Current liabilities Rs m462,260545 84,865.1%   
Net working cap to sales %-323.744.3 -731.2%  
Current ratio x0.33.2 8.0%  
Inventory Days Days2748 54.8%  
Debtors Days Days474 1,081.1%  
Net fixed assets Rs m113,72712 955,689.9%   
Share capital Rs m36139 924.4%   
"Free" reserves Rs m264,0931,443 18,301.7%   
Net worth Rs m264,4541,482 17,844.4%   
Long term debt Rs m242,2060-   
Total assets Rs m726,8342,077 34,999.5%  
Interest coverage x1.76.7 24.7%   
Debt to equity ratio x0.90-  
Sales to assets ratio x0.11.3 11.3%   
Return on assets %11.12.6 426.9%  
Return on equity %19.43.0 641.9%  
Return on capital %10.34.3 239.4%  
Exports to sales %00-   
Imports to sales %024.5 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA659 0.0%   
Fx inflow Rs m15,11017 87,848.8%   
Fx outflow Rs m4,298673 638.4%   
Net fx Rs m10,813-656 -1,648.3%   
CASH FLOW
From Operations Rs m-159,66690 -177,406.6%  
From Investments Rs m-17,677105 -16,899.9%  
From Financial Activity Rs m186,503-14 -1,322,712.8%  
Net Cashflow Rs m9,364181 5,188.0%  

Share Holding

Indian Promoters % 52.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.0 3.8 105.3%  
FIIs % 26.6 0.1 26,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 21.2 77.8%  
Shareholders   93,274 4,783 1,950.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   PLETHICO PHARMA  BIOCON LTD  UNICHEM LAB  ALKEM LABORATORIES  AJANTA PHARMA  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Healthcare and Power Stocks Witness Buying(Closing)

Indian share markets continued to trade on a flat during closing hours of trade and ended the day marginally higher to close at fresh record high levels.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY19); Net Profit Down 152.5% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 1 bn (down 152.5% YoY). Sales on the other hand came in at Rs 29 bn (up 28.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7% (Quarterly Result Update)

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Aug 21, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - DR. DATSONS LABS COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS